Dermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating

MT Newswires Live2025-01-21

Dermata Therapeutics (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.

The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.

Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.

Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.

Price: 3.65, Change: -0.04, Percent Change: -0.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505277407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505277407","market":"fut","top_or_hot":-1,"title":"Dermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating","media":"MT Newswires Live","content":"<html><body><p> Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.</p><p>The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.</p><p>Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.</p><p>Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.</p><p>Price: 3.65, Change: -0.04, Percent Change: -0.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDermata, Revance Collaborate on Trial to Treat Chronic Armpit Sweating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-21 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.</p><p>The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.</p><p>Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.</p><p>Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.</p><p>Price: 3.65, Change: -0.04, Percent Change: -0.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2505277407","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505277407","pubTimestamp":1737473292,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dermata Therapeutics  and Revance Therapeutics  said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.Price: 3.65, Change: -0.04, Percent Change: -0.95","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4007":"制药","BK4585":"ETF&股票定投概念","RVNC":"Revance Therapeutics Inc","DRMA":"Dermata Therapeutics Inc","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Dermata与Revance合作进行治疗慢性腋窝出汗的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVNC":0.9,"DRMA":0.9},"content_text":"Dermata Therapeutics (DRMA) and Revance Therapeutics (RVNC) said Tuesday they signed a collaboration agreement for a clinical study that will evaluate the use of Dermata's xyngari with Revance's daxxify for the treatment of primary axillary hyperhidrosis, which is a chronic condition that causes excessive armpit sweating.The randomized 16-week phase 2a trial trial will compare xyngari with daxxify versus xyngari with placebo, tracking reductions in sweat production and other efficacy measures, the companies said.Dermata previously demonstrated positive safety and efficacy results when pairing xyngari with a botulinum toxin in early clinical trials, they added.Xyngari is a topical Spongilla powder that creates microchannels in the skin, supporting a needle-free method to deliver botulinum toxin, according to the companies.Price: 3.65, Change: -0.04, Percent Change: -0.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505277407","isCrawlerRequest":true}